ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CNCR ETF Series Solutions Trust Range Cancer Therapeutics

13.65
-0.23 (-1.66%)
After Hours
Last Updated: 17:16:11
Delayed by 15 minutes

Period:

Draw Mode:

Volume 87,405
Bid Price 12.28
Ask Price 14.83
News -
Day High 13.84

Low
9.22

52 Week Range

High
18.00

Day Low 13.65
Company Name Etf Ticker Symbol Market Type
ETF Series Solutions Trust Range Cancer Therapeutics CNCR NASDAQ Exchange Traded Fund
  Price Change Change Percent Etf Price Last Traded
-0.23 -1.66% 13.65 17:16:11
Open Price Low Price High Price Close Price Prev Close
13.82 13.65 13.84 13.65 13.88
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
72 87,405  13.72  1,199,408 - 9.22 - 18.00
Last Trade Time Type Quantity Etf Price Currency
16:00:00 1  13.65 USD

ETF Series Solutions Trust Range Cancer Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
10.92M 800.00k - 70k -4.62M -5.77 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News ETF Series Solutions Tru...

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CNCR Message Board. Create One! See More Posts on CNCR Message Board See More Message Board Posts

CNCR Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week14.4815.0113.6514.363,836-0.83-5.73%
1 Month14.9015.2413.6514.563,810-1.25-8.39%
3 Months15.9816.78113.6515.0812,983-2.33-14.58%
6 Months12.6018.0012.4715.9522,7411.058.33%
1 Year13.5918.009.2215.4412,9250.060.44%
3 Years30.7632.999.2216.738,930-17.11-55.62%
5 Years20.6335.8189.2220.709,991-6.98-33.83%

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

Your Recent History

Delayed Upgrade Clock